Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1708 · 2 trials · 2 indications
Blood samples will be collected to determine the AUC0-inf of MK-1708.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-1708 Dosage 1 | EXPERIMENTAL | Participants receive multiple doses of MK-1708 dosage 1. |
| MK-1708 Dosage 2 | EXPERIMENTAL | Participants receive multiple doses of MK-1708 dosage 2. |
| Placebo | PLACEBO_COMPARATOR | Participants receive multiple doses of placebo. |
| Period 1: MK-1708 | EXPERIMENTAL | Participants will receive a single oral dose of MK-1708 on Day 1. |
| Period 2: MK-1708 and Itraconazole | EXPERIMENTAL | A washout period of at least 10 days will occur between MK-1708 dosing in Period 1 and the first itraconazole dosing in Period 2. In Period 2, participants will receive itraconazole twice daily on Day 1 and once daily on Days 2 through Day 19. Participants will also receive a single oral dose of MK-1708 on Day 4. |
| Name | Type | Description |
|---|---|---|
| MK-1708 | DRUG | MK-1708 oral suspension |
| Placebo | DRUG | Placebo oral suspension |
| Itraconazole | DRUG | Oral administration |
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a...
Top 20 of 24 competitors
MK-1708 is an investigational small molecule being developed by Merck & Company, Inc. (MRK) for Alzheimer's disease. It is currently in Phase 1 clinical development, with studies conducted in healthy participants and healthy elderly participants to evaluate its safety and pharmacokinetics.
MK-1708 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is an investigational small molecule in Phase 1 clinical development for Alzheimer's disease.
MK-1708 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. Two Phase 1 studies have been completed, both in the United States, involving healthy participants and healthy elderly participants.
MK-1708 has been studied in two completed Phase 1 trials: NCT06586606, which evaluated the effects of itraconazole on MK-1708 in healthy participants with Alzheimer's disease, and NCT06647628, a study of MK-1708 in healthy elderly participants. Both trials were conducted in the United States.
MK-1708 is the investigational code name for this drug candidate. No alternative names have been disclosed, and it is not known to be the same as any other marketed or investigational drug.